GoodRx Holdings (GDRX) Debt to Equity (2019 - 2026)

GoodRx Holdings has disclosed Debt to Equity across 8 years of filings, most recently posting $0.78 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.78, up 4.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.78 (up 4.47% YoY), and the FY2025 annual result was $0.79, up 16.76% from the prior year.
• Debt to Equity came in at $0.78 for Q1 2026 at GoodRx Holdings, down from $0.79 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $1.04 in Q1 2024 to a low of $0.68 in Q4 2024.
• The 5-year median for Debt to Equity is $0.79 (2023), against an average of $0.81.
• Across the five-year window, Debt to Equity soared 32.92% in 2024 and retreated 27.59% in 2025, its largest moves.
• GoodRx Holdings' Debt to Equity stood at $0.81 in 2022, then climbed by 6.56% to $0.86 in 2023, then slipped by 21.24% to $0.68 in 2024, then climbed by 16.76% to $0.79 in 2025, then slipped by 1.09% to $0.78 in 2026.
• The last three Debt to Equity figures came in at $0.78 (Q1 2026), $0.79 (Q4 2025), and $0.81 (Q3 2025), per Business Quant data.